VEEDA CR, India’s fastest growing Clinical Research Organisation (CRO), has recently cleared the ANVISA inspection for the fourth consecutive time without any findings
FOR IMMEDIATE RELEASE / PRURGENT
VEEDA CR, India’s fastest growing Clinical Research Organisation (CRO), has recently cleared the ANVISA inspection for the fourth consecutive time without any findings, which enables Veeda to continue conducting studies for drugs to be marketed in Brazil.
Apurva Shah Co-Group Managing Director and Co- Founder, Veeda said, “The re-qualification by ANVISA for the 4th consecutive time has just further established and authenticated the high quality of work that we do at Veeda”
Binoy Group Co-Group Managing Director and Co- Founder, Veeda added “Quality is the keystone of Veeda. From the very beginning we ensured that not only are our facilities of the highest standard but so is the caliber of our people. This is why we continue to get work from 7 of the top 10 Global Pharmaceutical companies”
Veeda has also received approvals by the FDA, MHRA and WHO, as well as winner of Frost and Sullivan’s “Indian Clinical Research Organization of the Year 2009” and Frost and Sullivan’s “Partner of Choice” for phase I studies in 2007. Very recently Veeda UK has been awarded the MHRA Phase I Supplementary Accreditation which provides clinical trial volunteers and sponsors with additional reassurance and confidence that the Veeda Phase I Unit meets the very highest of industry safety standards.
Given Veeda’s track record in quality, they have passed the audits without any study related findings.
For further information, please contact:
Tel: +91 79 30013000 Ext: 297,
Email - priyanka.shahveedacr.com